Kastritis Efstathios, Anagnostopoulos Athanasios, Roussou Maria, Gika Dimitra, Matsouka Charis, Barmparousi Despina, Grapsa Irini, Psimenou Erasmia, Bamias Aristotle, Dimopoulos Meletios Athanasios
Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, School of Medicine, Athens, Greece.
Haematologica. 2007 Apr;92(4):546-9. doi: 10.3324/haematol.10759.
The impact of high dose dexamethasone containing regimens with or without the novel agents thalidomide and bortezomib on the reversal of renal failure (RF) was evaluated in 41 consecutive newly diagnosed patients with multiple myeloma (MM) treated in a single institution. RF was reversed in 73% of all patients within a median of 1.9 months. In patients treated with dexamethasone and novel agents (thalidomide and/or bortezomib) the reversibility rate was 80% within a median of 0.8 months. Severe RF and significant Bence Jones proteinuria were associated with a lower probability of RF reversal. Patients who responded to treatment achieved RF reversal more often than in those who did not (85% versus 56%, p=0.046). In conclusion, RF is reversible in the majority of newly diagnosed MM patients treated with high-dose dexamethasone containing regimens. The addition of novel agents induces a more rapid RF reversal.
在一家机构对41例连续新诊断的多发性骨髓瘤（MM）患者进行了评估，这些患者接受了含高剂量地塞米松的方案治疗，该方案联合或不联合新型药物沙利度胺和硼替佐米，以评估其对肾衰竭（RF）逆转的影响。所有患者中有73%在中位时间1.9个月内肾衰竭得到逆转。在接受地塞米松和新型药物（沙利度胺和/或硼替佐米）治疗的患者中，逆转率为80%，中位时间为0.8个月。严重肾衰竭和显著的本周氏蛋白尿与肾衰竭逆转的可能性较低相关。对治疗有反应的患者比无反应的患者更常出现肾衰竭逆转（85%对56%，p=0.046）。总之，在大多数接受含高剂量地塞米松方案治疗的新诊断MM患者中，肾衰竭是可逆的。添加新型药物可使肾衰竭逆转更快。
